AJMC February 21, 2021
A German-style fair value/pricing committee may be in the works for the United States. However, government payers still have work to do before implementing a value assessment system.
The adoption of a German-style drug pricing panel – which relies heavily on comparative clinical research conducted during the first year a drug or other treatment hits the market – is an idea that has captured the interest of President Biden’s health team. While this notion of injecting additional clinical and economic analyses into Medicare’s purchasing decisions is gaining currency, a vital question is left unanswered: What factors are essential to determining a therapy’s fair value?
Knowing whether we are getting the best outcome for the price of any...
Today's Sponsors
Today's Sponsor